Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer DOI
Ram W. Sabnis

ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 16(1), P. 10 - 11

Published: Dec. 4, 2024

Provided herein are novel bicyclic heterocyclic compounds as CD73 inhibitors, pharmaceutical compositions, use of such in treating cancer, and processes for preparing compounds.

Language: Английский

Dynamics of tertiary lymphoid structures and immune cross talk in early versus advanced colorectal cancer: potential implications for immunotherapy DOI Creative Commons
Zixu Chen,

Bang Hu,

Keyu Cai

et al.

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(6)

Published: April 26, 2025

Language: Английский

Citations

0
Potential mechanisms of cancer stem‐like progenitor T‐cell bio‐behaviours DOI Creative Commons
Ling Ni

Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(8)

Published: Aug. 1, 2024

In situations involving continuous exposure to antigens, such as chronic infections or cancer, antigen-specific CD8

Language: Английский

Citations

2
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer DOI
Ram W. Sabnis

ACS Medicinal Chemistry Letters, Journal Year: 2024, Volume and Issue: 16(1), P. 10 - 11

Published: Dec. 4, 2024

Provided herein are novel bicyclic heterocyclic compounds as CD73 inhibitors, pharmaceutical compositions, use of such in treating cancer, and processes for preparing compounds.

Language: Английский

Citations

0